IPO Subscription Tracker

2026-08-03

Aug. 3 IPO action brief: Braveheart Bio's $300M deal leads the week, but retail access is unverified

Braveheart Bio leads a biotech-heavy US IPO week with a $15-$17 range and an expected Aug. 6 debut, while no mainstream retail allocation is publicly verified and NASN TECH is the live Hong Kong deadline.

IPO Subscription Tracker

Three U.S. IPOs show on Webull through Aug. 23; no Hong Kong subscription is live

LYNX fell 11.4% on debut; Hong Kong's 3223 deadline passed overnight in U.S. time

LYNX reaches its Aug. 19 listing checkpoint with a $492M defense-tech deal — no retail window verified

XTERU prices at $10: a $200 million SPAC unit, not a retail IPO allocation

ADBT lists without an IPO price; 3223 is the live Hong Kong subscription

RVII prices at $25; Robinhood's IPO window is already closed

FOIL starts NYSE trading at $22; VOGX also debuts, no retail IPO window verified

FOIL's $20-$22 IPO is one day from NYSE trading; no retail allocation verified

Aug. 10 IPO brief: FOIL targets Aug. 12 listing, but no retail window is verified

Attovia prices at $17 and starts Nasdaq trading today; no retail IPO path verified

Attovia expands its IPO filing to 17M shares at an estimated $17, but retail access is still unverified

Aug. 3 IPO action brief: Braveheart Bio's $300M deal leads the week, but retail access is unverified